InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell’s latest podcast features Mel Engle, newly appointed CEO of Predictive Oncology Inc. (NASDAQ: POAI), as well as CFO Bob Myers and Mark Collins, Chief Technical Officer of the company’s Helomics subsidiary. During the briefing, Engle discussed his background before passing the microphone to Myers and Collins for updates on Predictive Oncology’s financial footing, current operations and goals for 2021.
“I’ve been on the board of Predictive Oncology for about four years, and, within the last year-and-a-half, I’ve been the Chairman of the Board,” Engle said. “Being in that kind of position, it’s easier for me to be able to step into this role. … I’ve been a CEO of many companies beforehand, the most notable of which is a pharmaceutical company that was called Dey Laboratories, which was a subsidiary of Merck. We were a $610 million company when sold to Mylan back in 2007. That was a pharmaceutical respiratory company, so I’m very familiar with the ins-and-outs of R&D and the notion of what Predictive Oncology is doing.”
Engle is also currently on the board of WindGap Medical, a startup focused on the development of an innovative EpiPen, and he previously served as CEO of cell separation company ThermoGenesis and orthobiologics firm Anika Therapeutics.
To hear the entire podcast and subscribe for future episodes, visit: https://podcast.bell2bell.com.
Next, CFO Bob Myers discussed Predictive Oncology’s current financial standing.
“We are in a great situation, probably the best situation that we’ve been in since the existence of the company in terms of our cash capability and the strength of our balance sheet,” Myers noted. “We have absolutely no liabilities other than your normal accounts payable, which are quite low. We have a lot of things going on in terms of the income that we expect to get this year and the projects that we have. I think that we are going into these projects in a strong position.”
Mark Collins then stepped into the spotlight to provide an update on all things Helomics.
“From Helomics’ perspective, possibly the most important thing that we’ve announced and are working on is our platform that brings together Helomics’ assets (a translatable assay, data on 150,000 patient tumor samples and a machine learning platform licensed from Carnegie Mellon University) as a fee-for-service platform for pharmaceutical companies to test their drugs against our cancer cell lines,” Collins added. “In addition, we also kicked off, at the beginning of this year, an internal drug repositioning project where we’re actually testing some known anti-cancer drugs against our patient cell lines, driven by the machine learning. We expect that to generate some proof data for the platform which informs the commercial discussion but also to generate some valuable intellectual property about those compounds and their activity against specific patient profiles.”
Join InvestorBrandNetwork’s Stuart Smith and three key executives from the Predictive Oncology Inc. (NASDAQ: POAI) team to learn more about Predictive Oncology’s current operations and its goals for the balance of 2021 and beyond.
To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.
The latest installment of The Bell2Bell Podcast continues to reinforce InvestorBrandNetwork’s commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series. For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine
The InvestorBrandNetwork (“IBN”) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.
For more information on IBN, visit https://www.InvestorBrandNetwork.com.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.